» Articles » PMID: 19555855

Cellular and Molecular Basis of Pulmonary Arterial Hypertension

Abstract

Pulmonary arterial hypertension (PAH) is caused by functional and structural changes in the pulmonary vasculature, leading to increased pulmonary vascular resistance. The process of pulmonary vascular remodeling is accompanied by endothelial dysfunction, activation of fibroblasts and smooth muscle cells, crosstalk between cells within the vascular wall, and recruitment of circulating progenitor cells. Recent findings have reestablished the role of chronic vasoconstriction in the remodeling process. Although the pathology of PAH in the lung is well known, this article is concerned with the cellular and molecular processes involved. In particular, we focus on the role of the Rho family guanosine triphosphatases in endothelial function and vasoconstriction. The crosstalk between endothelium and vascular smooth muscle is explored in the context of mutations in the bone morphogenetic protein type II receptor, alterations in angiopoietin-1/TIE2 signaling, and the serotonin pathway. We also review the role of voltage-gated K(+) channels and transient receptor potential channels in the regulation of cytosolic [Ca(2+)] and [K(+)], vasoconstriction, proliferation, and cell survival. We highlight the importance of the extracellular matrix as an active regulator of cell behavior and phenotype and evaluate the contribution of the glycoprotein tenascin-c as a key mediator of smooth muscle cell growth and survival. Finally, we discuss the origins of a cell type critical to the process of pulmonary vascular remodeling, the myofibroblast, and review the evidence supporting a contribution for the involvement of endothelial-mesenchymal transition and recruitment of circulating mesenchymal progenitor cells.

Citing Articles

GATA2 participates in protection against hypoxia-induced pulmonary vascular remodeling.

Shirota Y, Ohmori S, Engel J, Moriguchi T PLoS One. 2024; 19(12):e0315446.

PMID: 39739870 PMC: 11687799. DOI: 10.1371/journal.pone.0315446.


Structural and functional determination of peptide versus small molecule ligand binding at the apelin receptor.

Williams T, Verdon G, Kuc R, Currinn H, Bender B, Solcan N Nat Commun. 2024; 15(1):10714.

PMID: 39730334 PMC: 11680790. DOI: 10.1038/s41467-024-55381-w.


Exercise improves systemic metabolism in a monocrotaline model of pulmonary hypertension.

Poojary G, Vasishta S, Thomas R, Satyamoorthy K, Padmakumar R, Joshi M Sports Med Health Sci. 2024; 7(1):37-47.

PMID: 39649790 PMC: 11624410. DOI: 10.1016/j.smhs.2024.03.001.


Targeting Soluble TGF-β Factors: Advances in Precision Therapy for Pulmonary Arterial Hypertension.

Becher C, Wits M, de Man F, Sanchez-Duffhues G, Goumans M JACC Basic Transl Sci. 2024; 9(11):1360-1374.

PMID: 39619136 PMC: 11604486. DOI: 10.1016/j.jacbts.2024.04.005.


The Intersection of HIV and Pulmonary Vascular Health: From HIV Evolution to Vascular Cell Types to Disease Mechanisms.

Garcia A, Almodovar S J Vasc Dis. 2024; 3(2):174-200.

PMID: 39464800 PMC: 11507615. DOI: 10.3390/jvd3020015.


References
1.
Remillard C, Tigno D, Platoshyn O, Burg E, Brevnova E, Conger D . Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am J Physiol Cell Physiol. 2007; 292(5):C1837-53. DOI: 10.1152/ajpcell.00405.2006. View

2.
Chu D, Sullivan C, Du L, Cho A, Kido M, Wolf P . A new animal model for pulmonary hypertension based on the overexpression of a single gene, angiopoietin-1. Ann Thorac Surg. 2004; 77(2):449-56. DOI: 10.1016/S0003-4975(03)01350-X. View

3.
Cowan K, Jones P, Rabinovitch M . Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis. Circ Res. 1999; 84(10):1223-33. DOI: 10.1161/01.res.84.10.1223. View

4.
Hong K, Lee Y, Lee E, Park S, Han C, Beppu H . Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation. 2008; 118(7):722-30. PMC: 3920834. DOI: 10.1161/CIRCULATIONAHA.107.736801. View

5.
Christman B, McPherson C, Newman J, King G, Bernard G, GROVES B . An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992; 327(2):70-5. DOI: 10.1056/NEJM199207093270202. View